Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 17/20 | 0.57 |
| ▸ | BRAF | P15056 | 16/20 | 0.57 |
| ▸ | CSF1R | P07333 | 1/20 | 0.56 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21516 | 0.89 | BTK (0.62) | BTK | |
| SCHEMBL19708 | 0.83 | JAK2 (0.46) | RAF1BRAFCSF1RDAPK1LCK | |
| SCHEMBL20394 | 0.78 | JAK3 (0.57) | CSF1RLCKKDR | |
| SCHEMBL19568 | 0.77 | MTOR (0.53) | RAF1BRAF | |
| SCHEMBL20369 | 0.75 | JAK2 (0.56) | BTK | |
| SCHEMBL20147 | 0.74 | JAK2 (0.55) | BTK | |
| SCHEMBL4918694 | 0.74 | SYK (0.65) | RAF1BRAFCSF1RLCKKDR | |
| SCHEMBL14070242 | 0.73 | BTK (0.69) | RAF1BRAFCSF1RDAPK1LCK | |
| SCHEMBL16078181 | 0.73 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL21597 | 0.73 | JAK2 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609098-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-13 | — | — | EP | claimed |
| EP-2609098-A1 | TRIAZOLOPYRAZINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| WO-2012025186-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-2609098-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-13 | — | — | EP | disclosed |
| EP-2609098-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| EP-2609098-A1 | TRIAZOLOPYRAZINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025186-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025186-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | SYK, IRAK1, ZAP70 | RAF1 82/4885BRAF 390/4885CSF1R 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.